Dry Eye

Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg and 0.3 mg formulations compared with vehicle hydrogel insert.

Product stimulates basal tear production, restores tear film homeostasis, and relieves symptoms.

Aldeyra Therapeutics announced today that it has achieved the primary endpoint of ocular redness in its randomly assigned, double-masked, vehicle-controlled Phase 2 clinical trial in dry eye disease.

Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S

Investigators find that estradiol drops can ease signs and symptoms of DED.

A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.

Timely diagnosis and successful intervention are key to successful treatment.

Experts provide perspectives on current care and pipeline products.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

Cynthia Matossian, MD, FACS, discusses the short- and long-term treatment options for dry eye flares.

Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.

Dr Matossian explains the importance of treating dry eye flares and what can happen if they are left unchecked.

Dr Matossian elaborates on how both patients’ and physicians’ awareness of dry eyes flares affects their eyesight and how they move forward with treatment.

Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

Unique clinical trials and novel products of interest currently under investigation for the treatment of dry eye disease.

A panel of ophthalmologists and optometrists conclude a discussion about dry eye disease by commenting on advances occurring in the field and future expectations for managing patients.

Strategies that can help eye care specialists work with patients to establish and stick to treatment plans for dry eye disease.

Types of in-office procedures currently being used by ophthalmologists and optometrists to aid in the treatment of dry eye disease.

Eye care specialists describe when corticosteroid therapy should be considered to treat dry eye disease and describe best practices when treating pre-surgical patients.

The most common types of artificial tears recommended to help manage dry eye disease and the importance of proper use for full benefit.

Eye care professionals discuss their comfort in recommending oral omega-3 fatty acids to help treat dry eye disease.

Increased time on digital devices and erratic schedules have disrupted patients’ management of their MGD and dry eye disease.

How to select and discuss sequential therapy with patients who have dry eye disease and set expectations for treatment.